Monopar Therapeutics Inc, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jeet Mukherjee from BTIG maintained a Buy rating on the stock and has a $104.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jeet Mukherjee has given his Buy rating due to a combination of factors that highlight the promising potential of Monopar Therapeutics Inc. The recent presentation of preclinical and clinical data at the AASLD conference provided insights into the biodistribution of ALXN1840, a compound being developed for Wilson’s Disease. The data revealed that while the compound, in its tripartite complex form, travels to various organs, it effectively reduces overall copper levels in the body without accumulation, which is a significant finding for the treatment’s safety and efficacy.
Moreover, additional patient data from a phase 2 copper balance study showed a statistically significant increase in fecal copper excretion, reinforcing the compound’s ability to promote copper elimination. The long-term safety profile was also supported by six years of serum creatinine data, showing normal levels throughout the period. These findings collectively enhance the confidence in ALXN1840’s benefit-risk profile and support the upcoming NDA submission, justifying the Buy rating.
In another report released today, Lake Street also maintained a Buy rating on the stock with a $106.00 price target.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MNPR in relation to earlier this year.